Quarterly Results

Moderna Reports Q1 2025 Results: Revenue Dips, Focus Shifts to Oncology Amid Expense Cuts

By Ajmal Aseem
4 May 2025

Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst [Read More…]

Business News

Eli Lilly Reported a Very Strong Start to 2025, Characterized by Significant Revenue Growth

By Athulya B S
1 May 2025

Revenue reached $12.73 billion, a substantial 45% increase year-over-year, primarily fueled by strong volume growth from Mounjaro and Zepbound.

Tag: Quarterly Results

Moderna Reports Q1 2025 Results: Revenue Dips, Focus Shifts to Oncology Amid Expense Cuts

Eli Lilly Reported a Very Strong Start to 2025, Characterized by Significant Revenue Growth

Areas Covered

Discover More

Eli Lilly Retatrutide Black Market Draws Six New U.S. Lawsuits From Drugmaker

Novo Nordisk Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes, Now Available Nationwide in the US

Charles River Laboratories Q2 2026 Earnings: Revenue Hits $1.00 Billion as Company Raises Full-Year Guidance

Moderna mFLUSIVA FDA Approval: Moderna Receives U.S. FDA Approval for Seasonal Influenza Vaccine mFLUSIVA

Eli Lilly Q2 2026 Earnings Jump 48% as Mounjaro, Zepbound Fuel Growth; Company Raises Full-Year Guidance

Biocon Q1 FY27 Revenue Rises 10% to Rs 4,336 Crore as Biopharma Business Leads Growth